• Latest Earnings
  • Equities
    Stock Analysis
    Stock Movers
    Deals
    Gainers And Losers
  • IPOs
  • Technology
    Artificial Intelligence
  • Web Stories
  • Benzinga Inspire

    Cipla

    6 months ago
    Cipla Skyrockets Over 8% After Dodging Major U.S. Regulatory Hurdle, Paving Way For Much-Awaited Drug LaunchThis is a major relief for the pharmaceutical industry company as it paves the way for an earlier-than-expected approval and launch of cancer drug gAbraxane.
    6 months ago
    Cipla's Q2 Net Profit Climbs 15.2% To ₹1,302.53 Cr, Beats Estimates
    9 months ago
    Cipla Shares Shoot Up After Q1 Profit Goes Up 18% To Beat Estimates As U.S. Business Shines
    6 months ago
    Cipla Skyrockets Over 8% After Dodging Major U.S. Regulatory Hurdle, Paving Way For Much-Awaited Drug Launch
    6 months ago
    Cipla's Q2 Net Profit Climbs 15.2% To ₹1,302.53 Cr, Beats Estimates
    9 months ago
    Cipla Shares Shoot Up After Q1 Profit Goes Up 18% To Beat Estimates As U.S. Business Shines
    Cipla Shares Soar 4% After Promoters Sell Stake
    May 15, 2024, 7:54 AM
    |Cipla shares zoomed 4% on Wednesday after the company's promoters sold over 2% stake in the company.
    Cipla Shares Soar 6% As Q4 Numbers Impresses Brokearges, Investors
    May 13, 2024, 4:49 AM
    |Cipla's share price was surging at the bourses on Monday after the company's March quarter results impressed investors. The stock went up 6% to hit an intraday high of ₹1,425.95.
    Loading...
    • Terms & Conditions
    • Do Not Sell My Personal Data/Privacy Policy
    • Disclaimer
    © 2025 Benzinga | All Rights Reserved